CN1376070A - 用于治疗子宫内膜组织子宫外增生、慢性骨盆疼痛和输卵管梗阻的方法 - Google Patents

用于治疗子宫内膜组织子宫外增生、慢性骨盆疼痛和输卵管梗阻的方法 Download PDF

Info

Publication number
CN1376070A
CN1376070A CN00813196A CN00813196A CN1376070A CN 1376070 A CN1376070 A CN 1376070A CN 00813196 A CN00813196 A CN 00813196A CN 00813196 A CN00813196 A CN 00813196A CN 1376070 A CN1376070 A CN 1376070A
Authority
CN
China
Prior art keywords
antagonist
administered
short
lhrh antagonist
lhrh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00813196A
Other languages
English (en)
Chinese (zh)
Inventor
J·恩格尔
H·利瑟穆勒－温赞
R·费尔比尔保穆
K·狄德里啻
W·库皮克尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeterna Zentaris GmbH
Original Assignee
Zentaris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris AG filed Critical Zentaris AG
Publication of CN1376070A publication Critical patent/CN1376070A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN00813196A 1999-09-23 2000-09-20 用于治疗子宫内膜组织子宫外增生、慢性骨盆疼痛和输卵管梗阻的方法 Pending CN1376070A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15547899P 1999-09-23 1999-09-23
US60/155,478 1999-09-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2007100789192A Division CN101045155A (zh) 1999-09-23 2000-09-20 用于治疗子宫内膜组织子宫外增生、慢性骨盆疼痛和输卵管梗阻的方法

Publications (1)

Publication Number Publication Date
CN1376070A true CN1376070A (zh) 2002-10-23

Family

ID=22555601

Family Applications (2)

Application Number Title Priority Date Filing Date
CN00813196A Pending CN1376070A (zh) 1999-09-23 2000-09-20 用于治疗子宫内膜组织子宫外增生、慢性骨盆疼痛和输卵管梗阻的方法
CNA2007100789192A Pending CN101045155A (zh) 1999-09-23 2000-09-20 用于治疗子宫内膜组织子宫外增生、慢性骨盆疼痛和输卵管梗阻的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2007100789192A Pending CN101045155A (zh) 1999-09-23 2000-09-20 用于治疗子宫内膜组织子宫外增生、慢性骨盆疼痛和输卵管梗阻的方法

Country Status (22)

Country Link
EP (1) EP1214086A2 (https=)
JP (2) JP2003509467A (https=)
KR (1) KR100772852B1 (https=)
CN (2) CN1376070A (https=)
AU (1) AU769482B2 (https=)
BG (1) BG66128B1 (https=)
BR (1) BR0014198A (https=)
CA (1) CA2383510A1 (https=)
HK (1) HK1049117A1 (https=)
HU (1) HUP0202741A3 (https=)
IL (1) IL148185A0 (https=)
MX (1) MXPA02002436A (https=)
NO (1) NO331198B1 (https=)
NZ (1) NZ534836A (https=)
PL (1) PL201898B1 (https=)
RU (1) RU2255759C2 (https=)
SK (1) SK3752002A3 (https=)
TR (1) TR200200738T2 (https=)
TW (1) TWI267373B (https=)
UA (1) UA73956C2 (https=)
WO (1) WO2001021194A2 (https=)
ZA (1) ZA200201374B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10157628A1 (de) * 2001-11-26 2003-06-12 Zentaris Ag Injektionslösung eines LHRH-Antagonisten
US7214662B2 (en) 2001-11-27 2007-05-08 Zentaris Gmbh Injectable solution of an LHRH antagonist
PT2252627T (pt) 2008-01-24 2017-07-24 Esperance Pharmaceuticals Constructos de fusão de domínio lítico e métodos para produzir e utilizar os mesmos
US20120053122A1 (en) * 2009-01-22 2012-03-01 Maatschap Interne Geneeskunde Rijnstate Method for the prophylaxis or treatment of flushing
AU2013337926B2 (en) 2012-10-30 2017-12-21 Esperance Pharmaceuticals, Inc. Antibody/drug conjugates and methods of use
US10881659B2 (en) 2013-03-15 2021-01-05 Abbvie Inc. Methods of treating heavy menstrual bleeding
US12083227B2 (en) 2017-08-18 2024-09-10 Abbvie Inc. Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis
MX2020001877A (es) 2017-08-18 2020-09-14 Abbvie Inc Formulaciones farmacéuticas para tratar la endometriosis, los fibromas uterinos, el síndrome de ovario poliquístico o la adenomiosis.
CN112261942A (zh) 2018-04-19 2021-01-22 艾伯维公司 治疗重度月经出血的方法
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064939A (en) * 1990-02-06 1991-11-12 The Salk Institute For Biological Studies Cyclic gnrh antagonists
SE9301606D0 (sv) * 1993-05-07 1993-05-07 Per-Christer Oden Composition for the treatment of impaired hair growth
IL114655A (en) * 1994-07-22 2005-08-31 Hampton Roads Medical College USE OF GnRH ANTAGONIST IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF A GONADAL-STEROID DEPENDENT CONDITION IN A MAMMAL
US5658884A (en) * 1994-07-22 1997-08-19 The Medical College Of Hampton Roads Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
DE19513662A1 (de) * 1995-04-08 1996-10-10 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE19604231A1 (de) * 1996-01-29 1997-07-31 Schering Ag Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen
RU2108583C1 (ru) * 1996-07-29 1998-04-10 Николай Владимирович Рымашевский Способ определения показаний к проведению гормонотерапии у больных генитальным эндометриозом
WO1998009645A1 (en) * 1996-09-04 1998-03-12 Dott Research Laboratory Peptide-containing drug compositions for oral administration
WO1998055470A1 (en) * 1997-06-05 1998-12-10 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
DE19911771B4 (de) * 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung

Also Published As

Publication number Publication date
CA2383510A1 (en) 2001-03-29
NO20021430D0 (no) 2002-03-21
RU2255759C2 (ru) 2005-07-10
BG66128B1 (bg) 2011-06-30
NO20021430L (no) 2002-05-07
NO331198B1 (no) 2011-10-31
TWI267373B (en) 2006-12-01
WO2001021194A2 (en) 2001-03-29
JP2012051920A (ja) 2012-03-15
JP2003509467A (ja) 2003-03-11
HUP0202741A3 (en) 2003-12-29
PL201898B1 (pl) 2009-05-29
TR200200738T2 (tr) 2002-08-21
KR20020035879A (ko) 2002-05-15
KR100772852B1 (ko) 2007-11-02
EP1214086A2 (en) 2002-06-19
IL148185A0 (en) 2002-09-12
WO2001021194A3 (en) 2002-03-14
AU769482B2 (en) 2004-01-29
NZ534836A (en) 2007-07-27
HK1049117A1 (zh) 2003-05-02
PL353244A1 (en) 2003-11-03
CN101045155A (zh) 2007-10-03
ZA200201374B (en) 2002-10-30
UA73956C2 (en) 2005-10-17
AU7779200A (en) 2001-04-24
BR0014198A (pt) 2002-05-21
HUP0202741A2 (hu) 2003-01-28
BG106584A (bg) 2003-02-28
MXPA02002436A (es) 2003-02-12
SK3752002A3 (en) 2003-06-03

Similar Documents

Publication Publication Date Title
ES2423899T3 (es) Método para aumentar las concentraciones de testosterona y esteroides relacionados en las mujeres
JP2012051920A (ja) 子宮内膜組織の子宮外の増殖、慢性骨盤痛およびファロピウス管閉塞症を治療するための製剤学的組成物、前述の疾病を治療するための医薬を製造するためのｌｈｒｈアンタゴニスト又はｌｈｒｈアンタゴニストおよび活性剤の使用
ES2281551T3 (es) Metodo de prevencion o tratamiento de enfermedades ginecologicas benignas.
CN1159917A (zh) 基于天然雌激素的多相避孕制剂
JP5543920B2 (ja) 閉経前の女性におけるエストロゲン依存症状の治療
TW577735B (en) Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders
US20080255053A1 (en) Method for the therapeutic management of endometriosis
JP2012077020A (ja) ゲスターゲンとＧｎＲＨアンタゴニストとの組合せ医薬
WO2019207026A1 (en) A composition for treating one or more estrogen related diseases
JP3925688B2 (ja) ＧｎＲＨａ治療中および／またはＧｎＲＨａ治療後の副作用を治療するための製薬学的調剤
HK1107262A (en) Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction
CN1845723B (zh) 子宫内膜异位症的治疗方法
JP5020811B2 (ja) 子宮内膜症および子宮腺筋症の治療剤および予防剤
WO2024197239A1 (en) Bioadhesive compositions and a method of treating endometriosis with aromatase inhibitors without increased gonadatroprin production
Ylikorkala Gonadotropin Releasing Hormone Analogues in Gynaeocology
HK1015711A (zh) 治療不育症的lhrh-拮抗劑

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1049117

Country of ref document: HK